Emerging therapies for Achondroplasia: changing the rules of the game

References

• Legeai-Mallet L, Savarirayan R. Novel therapeutic approaches for the treatment of achondroplasia. Bone. 2020;141:115579.
   PubMed Web of Science ®Google Scholar
• Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet. 2007;370(9582):162–172.
   PubMed Web of Science ®Google Scholar
• Hoover-Fong J, Cheung MS, Fano V, et al. Lifetime impact of achondroplasia: current evidence and perspectives on the natural history. Bone. 2021;146:115872.
   PubMed Web of Science ®Google Scholar
• Ireland PJ, Pacey V, Zankl A, et al. Optimal management of complications associated with achondroplasia. Appl Clin Genet. 2014;7:117–125.
   PubMedGoogle Scholar
• Deng C, Wynshaw-Boris A, Zhou F, et al. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell. 1996;84(6):911–921.
   PubMed Web of Science ®Google Scholar
• Matsushita M, Kitoh H, Mishima K, et al. Physical, Mental, and Social Problems of Adolescent and Adult Patients with Achondroplasia. Calcif Tissue Int. 2019;104(4):364–372.
   PubMed Web of Science ®Google Scholar
• Chilbule SK, Dutt V, Madhuri V. Limb lengthening in achondroplasia. Indian J Orthop. 2016;50(4):397–405.
   PubMed Web of Science ®Google Scholar
• Schiedel F, Rödl R. Lower limb lengthening in patients with disproportionate short stature with achondroplasia: a systematic review of the last 20 years. Disabil Rehabil. 2012;34(12):982–987.
   PubMed Web of Science ®Google Scholar
• Ko KR, Shim JS, Chung CH, et al. Surgical Results of Limb Lengthening at the Femur, Tibia, and Humerus in Patients with Achondroplasia. Clin Orthop Surg. 2019;11(2):226–232.
   PubMed Web of Science ®Google Scholar
• Park KW, Garcia RA, Rejuso CA, et al. Limb Lengthening in Patients with Achondroplasia. Yonsei Med J. 2015;56(6):1656–1662.
   PubMed Web of Science ®Google Scholar
• Harada D, Namba N, Hanioka Y, et al. Final adult height in long-term growth hormone-treated achondroplasia patients. Eur J Pediatr. 2017;176(7):873–879.
   PubMed Web of Science ®Google Scholar
• Hertel NT, Eklöf O, Ivarsson S, et al. Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial. Acta Paediatr. 2005;94(10):1402–1410.
   PubMed Web of Science ®Google Scholar
• Kanaka-Gantenbein C. Present status of the use of growth hormone in short children with bone diseases (diseases of the skeleton). J Pediatr Endocrinol Metab. 2001;14(1):17–26.
   PubMed Web of Science ®Google Scholar
• Bagley CA, Pindrik JA, Bookland MJ, et al. Cervicomedullary decompression for foramen magnum stenosis in achondroplasia. J Neurosurg. 2006;104(3 Suppl):166–172.
   PubMed Web of Science ®Google Scholar
• Hoover-Fong J, Scott CI, Jones MC; Committee On G. Health Supervision for People With Achondroplasia. Pediatrics. 2020;145:6.
   Web of Science ®Google Scholar
• Fredwall SO, Steen U, de Vries O, et al. High prevalence of symptomatic spinal stenosis in Norwegian adults with achondroplasia: a population-based study. Orphanet J Rare Dis. 2020;15(1):123.
   PubMed Web of Science ®Google Scholar
• Carlisle ES, Ting BL, Abdullah MA, et al. Laminectomy in patients with achondroplasia:</L> the impact of time to surgery on long-term function. Spine (Phila Pa 1976). 2011;36(11):886–892.
   PubMed Web of Science ®Google Scholar
• Yasoda A, Komatsu Y, Chusho H, et al. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med. 2004;10(1):80–86.
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Marie PJ. Fibroblast growth factor signaling in skeletal development and disease. Genes Dev. 2015;29(14):1463–1486.
   PubMed Web of Science ®Google Scholar
• Legeai-Mallet L, Benoist-Lasselin C, Munnich A, et al. Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. Bone. 2004;34(1):26–36.
   PubMed Web of Science ®Google Scholar
• Chusho H, Tamura N, Ogawa Y, et al. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci U S A. 2001;98(7):4016–4021.
   PubMed Web of Science ®Google Scholar
• Yasoda A, Ogawa Y, Suda M, et al. Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. J Biol Chem. 1998;273(19):11695–11700.
   PubMed Web of Science ®Google Scholar
• Gonçalves D, Rignol G, Dellugat P, et al. In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PloS One. 2020;15(12):e0244368.
   PubMed Web of Science ®Google Scholar
• Komla-Ebri D, Dambroise E, Kramer I, et al. Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model. J Clin Invest. 2016;126(5):1871–1884.
   PubMed Web of Science ®Google Scholar
• Lorget F, Kaci N, Peng J, et al. Evaluation of the thera peutic potential of a CNP analog in a Fgfr3 mouse model recap itulating achondroplasia. Am J Hum Genet. 2012;91(6):1108–1114.
   PubMed Web of Science ®Google Scholar
• Savarirayan R, Irving M, Bacino CA, et al. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia. N Engl J Med. 2019;381(1):25–35.
   PubMed Web of Science ®Google Scholar
• Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020;396(10252):684–692.
   PubMed Web of Science ®Google Scholar
• Savarirayan R, Tofts L, and Irving M, et al. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genet Med. 2021 Aug 2:1–5. doi:https://doi.org/10.1038/s41436-21-01287-7.
   Google Scholar
• Savarirayan R, Irving M, Maixner W, et al. Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery. Sci Prog. 2021;104(1):368504211003782.
   PubMed Web of Science ®Google Scholar
• Breinholt VM, Rasmussen CE, Mygind PH, et al. TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias. J Pharmacol Exp Ther. 2019;370(3):459–471.
   PubMed Web of Science ®Google Scholar
• Jin L, Nonaka Y, Miyakawa S, et al. Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain. Mol Ther. 2016;24(11):1974–1986.
   PubMed Web of Science ®Google Scholar
• Necchi A, Castellano DE, Mellado B, et al. Fierce-21: phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC). J clin oncol. 2019;37(7_suppl):409.
   Google Scholar
• Ozaki T, Kawamoto T, Iimori Y, et al. Evaluation of FGFR inhibitor ASP5878 as a drug candidate for achondroplasia. Sci Rep. 2020;10(1):20915.
   PubMed Web of Science ®Google Scholar
• Yamashita A, Morioka M, Kishi H, et al. Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature. 2014;513(7519):507–511.
   PubMed Web of Science ®Google Scholar
• Fafilek B, Hampl M, Ricankova N, et al. Statins do not inhibit the FGFR signaling in chondrocytes. Osteoarthritis Cartilage. 2017;25(9):1522–1530.
   PubMed Web of Science ®Google Scholar